FDA Approves Astellas Myrbetriq for OAB Treatment
The drug Myrbetriq which has been approved by FDA for use in OAB patients will be available in all worldwide pharmacies in the last quarter of the year is found to enhance the storage of bladder along with alleviating the patients' need of frequent urination, which is normally involuntary.
- Aguadilla-Isabela-San Sebastian, PR (1888PressRelease) August 19, 2012 - The Astellas Pharma US, Inc's extended release tablets of Myrbetriq has been approved by the FDA (Food and Drug Administration) for curing symptoms associated with overactive bladder (OAB) such as urinary frequency, urgency as well as an urge of urinary incontinence.
The drug Myrbetriq (mirabegron) is found to act as a beta-3 adrenergic agonist and has been extensively studied for a period of more than 10 years in almost 10,000 individuals.
The drug is believed to offer a unique and novel therapeutic option for patients suffering with overactive bladder and a far better approach than the currently available antimuscarinic medications.
This recently approved drug of Astellas, which has been invented as well as developed by the same company is an oral medication that is recommended to be taken once a day either with or without food with a starting dosage of 25 mg.
This dosage of 25 mg per day of Myrbetriq is found to execute its action within eight weeks and depending on the efficacy and tolerance of an individual, its dose can be increased to 50 mg per day.
Steven Ryder, president of the Pharma Global Development of Astellas said that Myrbetriq is the pioneer and novel oral drugs for treatment of OAB that employs a different action mechanism, since the advent of anticholinergic agents almost 30 years back.
He also added that the approval of Myrbetriq by the FDA depicts the implication of a significant clinical milestone in the treatment approach of OAB and it is their current commitment to enhance the urological health of the patients.
Keeping in mind the safety of the OAB patients, the FDA has restricted the use of Myrbetriq as well as cautioned the medical professionals for prescribing this drug in individuals with any major impairment of liver, uncontrolled hypertension as well as those with last-stage kidney complications.
For more: http://www.zeepharmacy.com/kamagra-jelly.html
Zeepharmacy.com
1600 Pennsylvania Ave, Washington, DC, USA - 20002
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam